has been cited by the following article(s):
[1]
|
CTLs, NK cells and NK-derived EVs against breast cancer
Human Immunology,
2023
DOI:10.1016/j.humimm.2023.03.001
|
|
|
[2]
|
Personalized dendritic cell vaccination in cancer therapy: An evidence-based research study
Journal of Cancer Research and Therapeutics,
2023
DOI:10.4103/jcrt.jcrt_522_21
|
|
|
[3]
|
CTLs, NK cells and NK-derived EVs against breast cancer
Human Immunology,
2023
DOI:10.1016/j.humimm.2023.03.001
|
|
|
[4]
|
Programmed Cell Death Protein 1 (PD-1) in Relation to PANoptosis: Immune
Pharmacological Targets for Management of Breast Adenocarcinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets,
2023
DOI:10.2174/1871530323666230213121803
|
|
|
[5]
|
Adoptive transfer of activated immune cells against solid tumors: A preliminary study
Cellular Immunology,
2022
DOI:10.1016/j.cellimm.2022.104616
|
|
|
[6]
|
Personalized dendritic cell vaccination in cancer therapy: An evidence-based research study
Journal of Cancer Research and Therapeutics,
2022
DOI:10.4103/jcrt.jcrt_522_21
|
|
|
[7]
|
Personalized dendritic cell vaccination in cancer therapy: An evidence-based research study
Journal of Cancer Research and Therapeutics,
2022
DOI:10.4103/jcrt.jcrt_522_21
|
|
|
[8]
|
A Review of Immunomodulatory Effects of Fluoroquinolones
Immunological Investigations,
2021
DOI:10.1080/08820139.2020.1797778
|
|
|